Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Boehringer Files Hernexeos for First-Line NSCLC Use in Japan
Boehringer Ingelheim has filed for a label expansion of Hernexeos (zongertinib) in Japan, seeking approval for use as a first-line treatment in patients with HER2 (ERBB2)-mutated unresectable, advanced or recurrent non-small cell lung cancer (NSCLC). Hernexeos hit the Japanese market…
To read the full story
Related Article
- Boehringer Sees Oncology as Pillar of Japan Business, Starting with Hernexeos
November 20, 2025
- Pluvicto, Imaavy, Hernexeos Now Available in Japan
November 13, 2025
BUSINESS
- Lilly Warns Against Off-Label Use of Mounjaro
June 11, 2026
- BMS Seeks Japan Approval for Mezigdomide in Multiple Myeloma
June 11, 2026
- SanBio Sees Akuugo Expanding to 20-30 Treatment Centers
June 11, 2026
- Rakuten Medical to Promote President Maeda to CEO
June 11, 2026
- Metagen Starts Global PI/II Trial of Oral FMT Therapy
June 11, 2026
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…